Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1179-6901
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? ; volume:17 ; number:3 ; day:11 ; month:8 ; year:2017 ; pages:461-467 ; date:9.2017
Drugs in R & D ; 17, Heft 3 (11.8.2017), 461-467, 9.2017

Schlagwort
Krebs
Onkologie

Urheber
Grassi, Paolo
Beteiligte Personen und Organisationen
Verzoni, Elena
Ratta, Raffaele
Porcu, Luca
Prisciandaro, Michele
Mennitto, Alessia
Calareso, Giuseppina
Braud, Filippo De
Procopio, Giuseppe
SpringerLink (Online service)

DOI
10.1007/s40268-017-0203-y
URN
urn:nbn:de:1111-201711295598
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:34 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Grassi, Paolo
  • Verzoni, Elena
  • Ratta, Raffaele
  • Porcu, Luca
  • Prisciandaro, Michele
  • Mennitto, Alessia
  • Calareso, Giuseppina
  • Braud, Filippo De
  • Procopio, Giuseppe
  • SpringerLink (Online service)

Ähnliche Objekte (12)

First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib

Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma

Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

Reversible Hypopigmentation with Pazopanib

Reversible Hypopigmentation with Pazopanib

Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report

Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report

Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report

Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Pembrolizumab as first-line treatment for metastatic uveal melanoma

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

Verbundene Objekte